Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 276 No 7392 p311
18 March 2006

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Pharmacy “tremendous” over oxygen crisis, says health minister

Sandra Gidley

Sandra Gidley: ministerial comments about phased handover misleading

Community pharmacy's response to the recent oxygen crisis has been acknowledged as “tremendous” by Liam Byrne, Parliamentary Under-Secretary of State for Health.

Mr Byrne said during a House of Commons adjournment debate on the matter: “The part played by many pharmacists in coming forward to ensure that patients’ needs came first was magnificent. Both the DoH and the NHS greatly appreciate their professionalism and commitment to patient care, which they have displayed in spades over the past few weeks.”

Mr Byrne was responding to criticism of the DoH’s handling of the introduction of the new home oxygen service. He maintained the Government’s position that there was to be a six-month transition period from 1 February for the 30,000 cylinder service patients in England. But he failed to apologise for the shambles into which the handover descended.

In the debate last week, pharmacist MP Sandra Gidley (Lib Dem, Romsey) said it had been clearly understood by pharmacists that they would not be able to supply oxygen after 1 February except in response to prescriptions written before that date. She said that ministerial statements, that the change from pharmacy supply to regional contractors was always intended to be phased in over six months, were misleading. The NHS Primary Care Contracting website had made it clear that GPs would not be able to prescribe oxygen after 1 February and supplies to 30,000 patients ceased abruptly on that date. She added that it was only DoH mismanagement that meant that regulations to stop GPs prescribing oxygen after that date never materialised. “I am not quite sure where the idea that there has been a transition period comes from, because it has certainly not been the perception of anyone who works in the industry.”

In a response to a letter to The Journal this week (p320), the NHS PCC apologies for any confusion its guidance may have caused.

Back to Top


©The Pharmaceutical Journal